Its purpose is to collect in one file information on all recorded cases of acute coronary occlusion in Iceland, together with information on risk factors and treatment among persons aged 25-74. It includes selected data on all cases of acute coronary occlusion diagnosed since 1981.
Holtasmári 1, 2. floor
201 Kópavogur
ICELAND
Phone: +354 535-1800
Fax: +354 535-1801
Email: afgreidsla@hjarta.is
Directorate of Health
Katrínartún 2
105 Reykjavík
Kt. 710169-5009
ICELAND
Phone + 354 510 1900
Email 1: mottaka@landlaeknir.is
Email 2: johannag@hjarta.is
1. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, Steingrimsdottir L, Critchley J, Bennett K, O'Flaherty M, Capewell S. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS One. 2010 Nov 12;5(11):e13957.
2. Aspelund T, Thorgeirsson G, Sigurdsson G, Gudnason V. Estimation of 10-year risk of fatal cardiovascular disease and coronary heart disease in Iceland with results comparable with those of the Systematic Coronary Risk Evaluation project. Eur J Cardiovasc Prev Rehabil. 2007 Dec;14(6):761-8.
3. Andresdottir MB, Sigfusson N, Sigvaldason H, Gudnason V. Erythrocyte sedimentation rate, an independent predictor of coronary heart disease in men and women: The Reykjavik Study. Am J Epidemiol. 2003 Nov 1;158(9):844-51.
4. Sigfusson N, Sigurdsson G, Agnarsson U, Gudmundsdottir II, Stefansdottir I, Sigvaldason H, Gudnason V. Declining coronary heart disease mortality in Iceland: contribution by incidence, recurrence and case fatality rate. Scand Cardiovasc J. 2002 Dec;36(6):337-41.
5. Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas AM, Pajak A. Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994 Jul;90(1):583-612.
B.R.I.D.G.E. TO DATA® is the most recent and updated version of the RAD-AR (Risk Assessment of Drugs-
The Estonian Drug Treatment Register was established in 2020. All health care providers treating drug dependence are required to send notification to the Register when starting or finishing a treatment episode. Each record contains personal identifiers (name and unique ID-code assigned to all residents of Estonia), socio-demographic characteristics, drugs used, date and code of diagnosis (ICD-10), as well as data on treatment episode.
Kersti Villand
Estonian Drug Treatment Register
National Institute for Health Development
Paldiski mnt 80
10617 Tallinn
ESTONIA
Email: kersti.villand@tai.ee
Estonian Drug Treatment Register
National Institute for Health Development
Paldiski mnt 80
10617 Tallinn
ESTONIA
Phone: +372 659 3900
Email 1: tai@tai.ee
Email 2: naris@tai.ee
N/A
The Registry for Monitoring Fetal Damage and Chromosomal Abnormalities contains information on birth defects since 1964. Data from the Swedish Medical Birth Register are available since 1973, and data from the Swedish Patient Register are available since 1987. This specific register contains information on newborns, live births and stillborn children, who have a gestational age of at least 22 completed weeks of pregnancy and who have congenital malformations, deformities and chromosomal abnormalities.
SOCIALSTYRELSEN
The National Board of Health and Welfare
Department of Registers and Statistics
SE-106 30 Stockholm
SWEDEN
Phone: +46 75 247 30 00
Email: E-mail address: RELA@socialstyrelsen.se
1. Segovia Chacón S, Karlsson P, Cesta CE. Detection of major congenital malformations depends on length of follow-up in Swedish National Health Register Data: implications for pharmacoepidemiological research on medication safety in pregnancy. Paediatr Perinat Epidemiol. 2024;38(6):521-531.
2. Gkekos L, Johansson ALV, Rodriguez-Wallberg KA, Fredriksson I, Lundberg FE. Obstetric and perinatal outcomes in women with previous breast cancer: a nationwide study of singleton births 1973-2017. Hum Reprod Open. 2024;2024(2):hoae027.
3. Cnattingius S, Källén K, Sandström A, Rydberg H, Månsson H, Stephansson O, Frisell T. The Swedish medical birth register during five decades: documentation of the content and quality of the register. Eur J Epidemiol. 2023;38:109-120.
4. Caldeman C, Fogelström A, Oddsberg J, Mesas Burgos C, Löf Granström A. National birth prevalence, associated anomalies and mortality for gastroschisis in Sweden. Acta Paediatr. 2021;110(9):2635-2640.
5. Al-Jebari Y, Rylander L, Ståhl O, Giwercman A. Risk of congenital malformations in children born before paternal cancer. JNCI Cancer Spectr. 2018;2(2):pky027.
6. Sabeti Rad Z, Friberg B, Henic E, Rylander L, Ståhl O, Källén B, Lingman G. Congenital malformations in offspring of women with a history of malignancy. Birth Defects Res. 2017;109(3):224-233.
7. Sabeti Rad Z, Friberg B, Henic E, Rylander L, Ståhl O, Källén B, Lingman G. Characteristics of the offspring of women with a history of malignancy, excluding congenital malformations. J Obstet Gynaecol Can. 2016;38(11):1037-1044.
8. Nikkilä A, Källén B, Marsál K. Fetal growth and congenital malformations. Ultrasound Obstet Gynecol. 2007;29(3):289-295.
9. Wennerholm UB, Bergh C, Hamberger L, Lundin K, Nilsson L, Wikland M, Källén B. Incidence of congenital malformations in children born after ICSI. Hum Reprod. 2000;15(4):944-948.
10. Källén B, Robert E, Harris J. Associated malformations in infants and fetuses with upper or lower neural tube defects. Teratology. 1998;57(2):56-63.
With data since 1987, the Estonian Tuberculosis (TB) Register is a population-based, centralized national register with standardized registration of all TB cases in Estonia. This TB Register is an electronic, person-based one with unique personal Estonian ID-codes, linking data with the Estonian Population Register, TB reference laboratory database, and Causes of Death Register. All data are cross-checked with health care providers.
